ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Elevated sclerostin levels in cerebrospinal fluid are associated with cognitive impairment in the Alzheimer's disease continuum.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bone-derived sclerostin impairs cognitive function in both patients with Alzheimer's disease (AD) and mouse models of AD. For the first time, we explored the correlation of sclerostin with neurocognitive domains in the AD continuum. Methods: Sclerostin levels were measured in the cerebrospinal fluid (CSF) of a cohort of individuals with biological evidence of AD pathology, including patients with AD dementia, mild cognitive impairment due to AD (MCI), and subjective memory complaints (SMC). Correlations were examined between sclerostin and domain-specific cognitive scores. Results: CSF sclerostin correlated with overall cognitive function, as well as with all cognitive domains impaired in AD. Of note, MCI patients with high CSF sclerostin levels displayed a worse overall and domain-specific neurocognitive performance. Discussion: Our results evidenced the negative impact of sclerostin on all the cognitive domains predominantly in prodromal AD, suggesting its potential role as a biomarker of cognitive decline in the early stages of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.